The cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
ProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells’ DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
Truven Health Analytics Poll Finds Opinions Split Between Cancer Patients, Non-Patients On High-Cost Drugs
Cancer patients may have a different point of view on oncology drug decisions than non-patients, according to a new poll conducted by Truven Health Analytics.
A Wayne State University researcher believes he has found a safer, more effective way to keep cancer cells from protecting themselves against tumor-killing drugs in cases of non-Hodgkin’s lymphoma.